Photo from wikipedia
To evaluate the number and nature of reported congenital malformations (CMs) after intrauterine exposure to non‐tumour necrosis factor inhibitor biologics (non‐TNFi biologics) compared to certolizumab pegol (CZP). Click to show full abstract
To evaluate the number and nature of reported congenital malformations (CMs) after intrauterine exposure to non‐tumour necrosis factor inhibitor biologics (non‐TNFi biologics) compared to certolizumab pegol (CZP).
Keywords:
necrosis factor;
reported congenital;
exposure non;
congenital malformations;
tumour necrosis;
non tumour
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!